Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Stem Cells Translational Medicine(2022)10.1093/stcltm/szab005Source: DataRank Database

Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products is a research paper published in Stem Cells Translational Medicine (2022). On theSindex it has a DataRank of 0. It has been cited 176 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access176 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: goldTopics (41)IDs (PubMed, PMC)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

James A. Ankrum ORCID,Scott D. Olson ORCID,Jan A. Nolta ORCID,Guido Moll ORCID

Live enrichment

PubMed:35641163 PMC:PMC8895495

BSRT

Grant: GSC203

NINDS

Grant: R21NS116302

National Institutes of Health

Grant: R01NS102486

National Institutes of Health

Grant: R24ODO21606

NIH HHS

Grant: R24 OD021606

European Commission

Grant: 733006

A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischemia accompanied by mechanistic studies

National Institutes of Health

Grant: 5R01NS102486-06

MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE

National Institutes of Health

Grant: 1R21NS116302-01

Reshaping MSC surface expression profiles to target inflammation following CNS trauma

European Commission

Grant: 779293

Placenta-expanded adherent stromal cells (PLX-PAD) as an innovative therapy for improving recovery and survival following hip fracture arthroplasty – HIPGEN, a multicenter phase III trial

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

Fraternal Order of Eagles

German Research Foundation

University of Texas Health Science Center at Houston

California Institute for Regenerative Medicine

German Federal Ministry of Education and Research

goldLicense: CC BY NC

publisherhttps://academic.oup.com/stcltm/article-pdf/11/1/2/42689911/szab005.pdf

repositoryhttps://escholarship.org/uc/item/8rr5d5xz

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8895495

Europe_PMChttps://europepmc.org/articles/PMC8895495

Europe_PMChttps://europepmc.org/articles/PMC8895495?pdf=render

MeSH Terms

Mesenchymal Stem CellsHumansThromboplastinMesenchymal Stem Cell TransplantationBlood Coagulation

Keywords

CoagulationThromboembolismCoagulopathyCellular TherapyHemocompatibilitySafety And EfficacyTissue SourceProduct DiversificationMesenchymal Stromal/stem Cells (Mscs)Tissue Factor/Cd142/Factor Iii/F3Medical BiotechnologyClinical Sciences610Regenerative MedicineMesenchymal Stem Cell TransplantationThromboplastinmesenchymal stromal/stem cellsStem Cell Research - Nonembryonic - Humanstem cells616HumansBlood CoagulationTransplantationBiomedical and Clinical Sciences5.2 Cellular and gene therapiesFactor IIIMesenchymal Stem CellsStem Cell Researchtissue factorF3PerspectiveCD142Patient SafetyBiochemistry and Cell Biologymesenchymal stromalBiomedical engineering

Sustainable Development Goals

SDG 3: 3. Good health